BONE BIOLOGICS CORPORATION: 10-Q filed 2022-08-11
What BONE BIOLOGICS CORPORATION reported in its quarterly report filed 2022-08-11 (fiscal Q2 2022): 19 published measures, 56 facts as tagged in accession 0001493152-22-021997.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-08-11
- Fiscal period
- fiscal Q2 2022
- Accession
- 0001493152-22-021997 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BONE BIOLOGICS CORPORATION filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 5,658,881 | USD | |
| At 2021-12-31 | 6,675,365 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 70,636 | USD | |
| At 2021-12-31 | 99,909 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 5,588,245 | USD | |
| At 2022-03-31 | 6,038,801 | USD | |
| At 2021-12-31 | 6,575,456 | USD | |
| At 2021-06-30 | -14,615,955 | USD | |
| At 2021-03-31 | -14,124,057 | USD | |
| At 2020-12-31 | -13,692,310 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | -469,304 | USD | 91 |
| 2022-01-01 to 2022-06-30 | -1,158,803 | USD | 181 |
| 2022-01-01 to 2022-03-31 | -689,499 | USD | 90 |
| 2021-04-01 to 2021-06-30 | -491,898 | USD | 91 |
| 2021-01-01 to 2021-06-30 | -923,645 | USD | 181 |
| 2021-01-01 to 2021-03-31 | -431,747 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-06-30 | -1,220,843 | USD | 181 |
| 2021-01-01 to 2021-06-30 | -763,964 | USD | 181 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-06-30 | 768,402 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | -71,634,410 | USD | |
| At 2021-12-31 | -70,475,607 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 10,350,579 | shares | 91 |
| 2022-01-01 to 2022-06-30 | 10,350,579 | shares | 181 |
| 2021-04-01 to 2021-06-30 | 2,911,333 | shares | 91 |
| 2021-01-01 to 2021-06-30 | 2,911,333 | shares | 181 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | -0.05 | USD/shares | 91 |
| 2022-01-01 to 2022-06-30 | -0.11 | USD/shares | 181 |
| 2021-04-01 to 2021-06-30 | -0.17 | USD/shares | 91 |
| 2021-01-01 to 2021-06-30 | -0.32 | USD/shares | 181 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-06-30 | 1,600 | USD | 181 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-06-30 | 171,592 | USD | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | -469,304 | USD | 91 |
| 2022-01-01 to 2022-06-30 | -1,157,203 | USD | 181 |
| 2021-04-01 to 2021-06-30 | -231,881 | USD | 91 |
| 2021-01-01 to 2021-06-30 | -412,805 | USD | 181 |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 469,304 | USD | 91 |
| 2022-01-01 to 2022-06-30 | 1,157,203 | USD | 181 |
| 2021-04-01 to 2021-06-30 | 231,881 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 412,805 | USD | 181 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 17,600 | USD | 91 |
| 2022-01-01 to 2022-06-30 | 54,000 | USD | 181 |
| 2021-04-01 to 2021-06-30 | 2,016 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 47,516 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 10,350,579 | shares | |
| At 2021-12-31 | 10,350,574 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 77,212,305 | USD | |
| At 2021-12-31 | 77,040,713 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | -469,304 | USD | 91 |
| 2022-01-01 to 2022-06-30 | -1,157,203 | USD | 181 |
| 2021-04-01 to 2021-06-30 | -491,898 | USD | 91 |
| 2021-01-01 to 2021-06-30 | -923,645 | USD | 181 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 451,704 | USD | 91 |
| 2022-01-01 to 2022-06-30 | 1,103,203 | USD | 181 |
| 2021-04-01 to 2021-06-30 | 229,865 | USD | 91 |
| 2021-01-01 to 2021-06-30 | 365,289 | USD | 181 |
Income taxes paid, net
Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-06-30 | 1,600 | USD | 181 |
Inspect the source
- Entity
- BONE BIOLOGICS CORPORATION / CIK 0001419554
- Captured
- 2026-09-20T08:02:52.100Z
- SEC response SHA-256
7c2684db7febb4ea6b03577e138dc91ed20e12534f1d96c178894d4b68a7b815
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001419554.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))